Specificity and modulation of the action of lactoferrin, a negative feedback regulator of myelopoiesis

He, Ben; DeSousa, M; Smithyman, A; Ralph, P; Hamilton, J; Kurland, Jeffrey I.; Bognacki, J

doi:10.1182/blood.v55.2.324.bloodjournal552324

Cited by 13 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lf has a high degree of structural homology with transferrin (Metz-Boutigue et al, 1984) and both of them have iron binding capacity. It has been suggested that Lf may play a role in iron transport and storage (Birgens et al, 1988) and a regulatory role during myelopoiesis (Broxmeyer et al, 1980). Stimulation of growth of neoplastic cells by Lf has also been described (Hashizume et al, 1987;Amouric et al, 1984).…”

mentioning

confidence: 99%

Lactoferrin binding sites and nuclear localization in K562(S) cells

Garrè

Bianchi‐Scarrǎ

Sirito

et al. 1992

Journal Cellular Physiology

101

View full text Add to dashboard Cite

Lactoferrin, a single chain cationic glycoprotein, present in the secondary granules of neutrophils, acts as a negative feedback regulator of myelopoiesis. Specific receptors for lactoferrin were detected on the surface of different hematopoietic cell types. The influence of lactoferrin on cell growth in culture has been reported. Interactions of lactoferrin with DNA were also demonstrated. In the present paper we confirm the presence of lactoferrin specific binding sites on K562 cells and we estimate the number of binding sites and the dissociation constant. By Western blotting analysis performed on K562 lysates we find a band of about 120 kDa responsible for specific binding of lactoferrin. We also show that lactoferrin, after binding at the cell surface, is internalized in a temperature dependent way and is immunologically detectable as a DNA-linked protein in nuclear extracts.

show abstract

mentioning

confidence: 99%

Lactoferrin binding sites and nuclear localization in K562(S) cells

Garrè

Bianchi‐Scarrǎ

Sirito

et al. 1992

Journal Cellular Physiology

101

View full text Add to dashboard Cite

show abstract

“…Pyrogen contamination is known to effect myelopoietic homeostasis both in vivo and in vitro. Bacterial lipopolysaccharide (LPS) at concentrations above 1 X lo5 nglml has been reported to abolish the CSF-inhibitory effect of lactoferrin when added to cultures [9]. It is unlikely that the LPS contamination of 0.75 ng/ml detected in our preparations could have affected our results.…”

Section: Discussionmentioning

confidence: 84%

“…The hypothesis that lactoferrin is a major regulator of granulopoiesis is based upon a 40 or 60% inhibition of the production of GM-CSF by Ia-antigen-positive monocytes and macrophages [8][9][10]341. Yet, other types of CSF (ie, interleukin-3, G-CSF, and CSF-1) have also been implicated in myelopoietic regulation [24,28,35].…”

Section: Discussionmentioning

confidence: 99%

“…Yet, other types of CSF (ie, interleukin-3, G-CSF, and CSF-1) have also been implicated in myelopoietic regulation [24,28,35]. In addition, there is no evidence of lactoferrin modulation of CSF production from other sources (ie, T-lymphocytes, fibroblasts, endothelial cells) [9,24]. However, one study found lactoferrin inhibition of colony growth only when both monocytes and a subset of T-lymphocytes were present together as the source of CSF [36].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In vivo study of lactoferrin and murine rebound myelopoiesis

Poppas¹,

Faith²,

Bierman³

1986

American J Hematol

View full text Add to dashboard Cite

Lactoferrin has been reported to inhibit the production of colony-stimulating factor (CSF); thus we sought to study its possible effects on myelopoiesis in vivo. The characteristics of rebound myelopoiesis in C57BL mice injected with a sublethal dose of cyclophosphamide (CY) were used to test lactoferrin for any granulopoietic activity. An experimental group received daily injections of 50 micrograms of human lactoferrin beginning 24 hr after CY injections. By measuring the total nucleated cellularity of the femoral marrow, the peripheral blood count, and the incorporation of tritiated thymidine by the marrow in six replicate experiments, no statistically significant difference was noted between the lactoferrin injected groups and the control groups. Neither the route of lactoferrin administration (i.v. or i.p.) nor the sex of the animal altered the myelopoietic recovery. Lactoferrin had no stimulatory or inhibitory effect on murine rebound myelopoiesis in vivo contrary to the reported in vitro results.

show abstract

“…The suggestion that lactoferrin derived from the secondary granuIes of neutrophils acts as a negative feedback regulator of granulopoiesis is an attractive concept which has recently received considerable attention (Broxmeyer, 1978(Broxmeyer, , 1979Broxmeyer et al, 1978Broxmeyer et al, , 1980aBroxmeyer et al, , b, 1983Bennett & Davis, 1981;Bagby et al, 1983;Gentile & Broxmeyer, 1983). Our results suggest that a decreased release of lactoferrin from the neutrophils of patients with myeloproliferative disorders results in a lower than normal suppression of GM-CSF release from mononuclear cells which in turn results in an increased myeloid progenitor cell proliferative activity.…”

Section: Discussionmentioning

confidence: 99%

Lactoferrin in the myeloproliferative disorders: a search for granulopoietic regulator defects

Brown¹,

Rickard²,

Kronenberg³

1985

Br J Haematol

View full text Add to dashboard Cite

Evidence of a defect in the negative feedback control of granulopoiesis in the myeloproliferative disorders is presented. Neutrophil release of lactoferrin, plasma lactoferrin concentration, the number of lactoferrin receptor sites on mononuclear cells and granulocyte-monocyte colony stimulating factor (GM-CSF) release from peripheral blood cells were determined in patients with myeloproliferative disorders and compared with normal individuals. There was a significantly (P less than 0.001) decreased release of lactoferrin from the neutrophils of patients with myeloproliferative disorders which could be responsible for a reduced suppression of GM-CSF release from mononuclear cells which in turn may be responsible for the increased myeloid proliferative activity in patients with myeloproliferative disorders.

show abstract

Specificity and modulation of the action of lactoferrin, a negative feedback regulator of myelopoiesis

Cited by 13 publications

References 0 publications

Lactoferrin binding sites and nuclear localization in K562(S) cells

Lactoferrin binding sites and nuclear localization in K562(S) cells

In vivo study of lactoferrin and murine rebound myelopoiesis

Lactoferrin in the myeloproliferative disorders: a search for granulopoietic regulator defects

Contact Info

Product

Resources

About